SCHEMBL6891278

SCHEMBL6891278

CC(=O)NCc1ncn2ccsc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.39
ALOX15 P16050 1/20 0.38
VHL P40337 1/20 0.36
TP53 P04637 4/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MAPK10 P53779 1/20 0.33
KMT2A Q03164 3/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
KDM4E B2RXH2 2/20 0.33
MAPT P10636 2/20 0.33
TSHR P16473 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 1/20 0.33
HSD17B10 Q99714 1/20 0.33
USP7 Q93009 1/20 0.32
SETDB1 Q15047 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6887765 0.77 TP53 (0.33) NPSR1ALOX15TP53NPC1RAB9A
SCHEMBL16136315 0.72 TP53 (0.58) ALOX15TP53NPC1RAB9ASMN1; SMN2
SCHEMBL6890542 0.69 KDM4E (0.39) NPSR1TP53NPC1RAB9ASMN1; SMN2
SCHEMBL6892971 0.68 KDM4E (0.33) TP53NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL21368373 0.67 KLKB1 (0.52) SETDB1
SCHEMBL8053507 0.66 ALOX15 (0.40) NPSR1ALOX15VHLTP53NPC1
SCHEMBL6889541 0.66 ALDH1A1 (0.35) TP53NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6887825 0.65 TP53 (0.32) TP53SMN1; SMN2L3MBTL1HTT
SCHEMBL24016470 0.65 GRIA2 (0.41) NPSR1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL2070480 0.64 NPSR1 (0.46) NPSR1SMN1; SMN2ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677331-B2 HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-13 US disclosed
US-20030149016-A1 Novel carbapenem derivatives KANO YUKO (JP) 2003-08-07 US disclosed
US-6458780-B1 IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND MEIJI SEIKA KAISHA, LTD. (JP) 2002-10-01 US disclosed
EP-1101766-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149016-A1 Novel carbapenem derivatives DPEP1, TMPRSS15, STK35 NPSR1 2052/4885ALOX15 2514/4885VHL 3596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.